A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASE

Parkinson's Disease Clinical Trial

Official title:

A STUDY TO EVALUATE THE EFFICACY OF CJH1 [CLR4001] IN THE TREATMENT OF PARKINSON'S DISEASE

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01684475
• Other study ID #: CJH1 Trial
• Status: Recruiting
• Phase: Phase 1/Phase 2
• First received: September 11, 2012
• Last updated: September 12, 2012
• Start date: September 2012
• Est. completion date: September 2013

Study information

• Verified date: September 2012
• Source: Alexandra Marine and General Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the ability of CJH1 to increase the sensitivity of dopamine receptors and thereby reduce symptoms of Parkinson's Disease.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 21
• Est. completion date: September 2013
• Est. primary completion date: September 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years to 85 Years

Eligibility

Inclusion Criteria:

• Patient's with Parkinson's disease

Exclusion Criteria:

• Contraindications to study medication

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Intervention

Drug:
• CJH1 (CLR4001)

Locations

Country	Name	City	State
Canada	Gateway Rural Health Research	Goderich	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Alexandra Marine and General Hospital

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduced signs and symptoms of Parkinson's disease	Reduced signs and symptoms of Parkinson's disease	8 weeks	Yes